Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients (Articolo in rivista)

Type
Label
  • Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients (Articolo in rivista) (literal)
Anno
  • 2006-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1158/1078-0432.CCR-05-2574 (literal)
Alternative label
  • Iacobucci I, Saglio G, Rosti, G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Marente S, Frassoni F, Paolini S, Montefusco E, Baccarini M, MArtinelli G, Ginema Working party (2006)
    Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    in Clinical cancer research (Print); American Association For Cancer Research, Philadelphia (Stati Uniti d'America)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Iacobucci I, Saglio G, Rosti, G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Marente S, Frassoni F, Paolini S, Montefusco E, Baccarini M, MArtinelli G, Ginema Working party (literal)
Pagina inizio
  • 3037 (literal)
Pagina fine
  • 3042 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 12 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 10 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Univ Bologna, Inst Hematol & Med Oncol Seragnoli, Mol Biol Unit, I-40138 Bologna, Italy ; Univ Turin, Dept Clin & Biol Sci, Div Hematol & Internal Med, Turin, Italy Univ Naples Federico II, CEINGE Biotecnol Avanzate, Naples, Italy ; Univ Naples Federico II, Dept Biochem & Med Biotechnol, Naples, Italy ; Osped Riuniti Bergamo, Div Hematol, I-24100 Bergamo, Italy ; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy ; Univ Siena, Dept Hematol, I-53100 Siena, Italy ; Univ Pavia, Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, Div Hematol, I-27100 Pavia, Italy ; San Martino Hosp, Dept Hematol, Genoa, Italy (literal)
Titolo
  • Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients (literal)
Abstract
  • Purpose: Most patients with chronic-phase chronic myeloid leukemia (CIVIL) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CIVIL patients with an imatinib-induced CCgR. Patients with late chronic phase CIVIL after IFN-alpha failure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/beta 2 microglobulin ratio % <0.0005 and as a 3-log reduction from median baseline value) already at the time of first achieving a CCgR have significantly longer cytogenetic remission durations than those without this magnitude of molecular response (P < 0.05). (literal)
Editore
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
Editore di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it